These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23894404)
1. Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Lai CY; Hsieh LL; Sung FC; Tang R; Bai CH; Wu FY; Chiou HY; Yeh CC PLoS One; 2013; 8(7):e69039. PubMed ID: 23894404 [TBL] [Abstract][Full Text] [Related]
2. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population. Gan Y; Li XR; Chen DJ; Wu JH Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245 [TBL] [Abstract][Full Text] [Related]
3. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681 [TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. Sreeja L; Syamala VS; Syamala V; Hariharan S; Raveendran PB; Vijayalekshmi RV; Madhavan J; Ankathil R J Cancer Res Clin Oncol; 2008 Jun; 134(6):645-52. PubMed ID: 17952468 [TBL] [Abstract][Full Text] [Related]
5. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713 [TBL] [Abstract][Full Text] [Related]
6. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895 [TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670 [TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213 [TBL] [Abstract][Full Text] [Related]
9. Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy. Zhai XH; Huang J; Wu FX; Zhu DY; Wang AC Oncol Res Treat; 2016; 39(7-8):440-6. PubMed ID: 27487108 [TBL] [Abstract][Full Text] [Related]
10. Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452 [TBL] [Abstract][Full Text] [Related]
11. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447 [TBL] [Abstract][Full Text] [Related]
12. Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Mangoni M; Bisanzi S; Carozzi F; Sani C; Biti G; Livi L; Barletta E; Costantini AS; Gorini G Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):52-8. PubMed ID: 20708344 [TBL] [Abstract][Full Text] [Related]
13. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074 [TBL] [Abstract][Full Text] [Related]
14. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Trabulus S; Guven GS; Altiparmak MR; Batar B; Tun O; Yalin AS; Tunckale A; Guven M Mol Biol Rep; 2012 Jun; 39(6):6995-7001. PubMed ID: 22302399 [TBL] [Abstract][Full Text] [Related]
15. DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences. Letkova L; Matakova T; Musak L; Sarlinova M; Krutakova M; Slovakova P; Kavcova E; Jakusova V; Janickova M; Drgova A; Berzinec P; Halasova E Mol Biol Rep; 2013 Sep; 40(9):5261-73. PubMed ID: 23673479 [TBL] [Abstract][Full Text] [Related]
16. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613 [TBL] [Abstract][Full Text] [Related]
17. XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Stern MC; Siegmund KD; Conti DV; Corral R; Haile RW Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2384-90. PubMed ID: 17164360 [TBL] [Abstract][Full Text] [Related]
18. DNA repair genes XPD and XRCC1 polymorphisms and risk of end-stage renal disease in Egyptian population. Radwan WM; Elbarbary HS; Alsheikh NM Ren Fail; 2015 Feb; 37(1):122-8. PubMed ID: 25310768 [TBL] [Abstract][Full Text] [Related]
19. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Stoehlmacher J; Park DJ; Zhang W; Groshen S; Tsao-Wei DD; Yu MC; Lenz HJ J Natl Cancer Inst; 2002 Jun; 94(12):936-42. PubMed ID: 12072547 [TBL] [Abstract][Full Text] [Related]
20. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]